Trial
NCT04998747
A Study of Subcutaneous (SC) AMG 701 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Amgen
Collaborators
—
Condition
Relapsed/Refractory Multiple Myeloma
Intervention
AMG 701
Why stopped
Amgen Decision to stop development of AMG 701 SC, not for safety reasons but for business reasons.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-09-27